Evidence map›Paper›PMID 39267076›Full record

ArticleDiagnostic pathology2024

Navigating the diagnostic gray zone: a challenging case of pancreatic high-grade neuroendocrine neoplasm.

Brooke Mullen, Albert L Sy, Priscila Dias Goncalves, M Lisa Zhang

Abstract readCase Reports
In one paragraph

Article in Diagnostic pathology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Brooke Mullen *Department of Pathology, Massachusetts General Hospital, 55 Fruit Street, 02114, Boston, MA, USA.
Albert L Sy *Department of Pathology, Massachusetts General Hospital, 55 Fruit Street, 02114, Boston, MA, USA.
Priscila Dias GoncalvesDepartment of Pathology, Massachusetts General Hospital, 55 Fruit Street, 02114, Boston, MA, USA.
M Lisa ZhangDepartment of Pathology, Massachusetts General Hospital, 55 Fruit Street, 02114, Boston, MA, USA. mlzhang@mgh.harvard.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGrade 3 neuroendocrine tumor (G3 PanNET) and poorly differentiated neuroendocrine carcinoma (PanNEC) of the pancreas are considered distinct entities from a biological and prognostic perspective but may have overlapping features complicating a definitive diagnosis. CASE PRESENTATION: A 52-year-old female presented with a pancreatic body mass and liver lesions. Initial biopsies showed variable lower- and higher-grade morphologies and modestly elevated Ki67 proliferation index up to 30%, leading to a diagnosis of G3 PanNET. The patient underwent everolimus treatment followed by surgical resection, revealing a complex tumor with features of both G3 PanNET and PanNEC, including admixed well- and poorly differentiated morphologies, modestly elevated hotspot Ki67 of 28%, retained ATRX/DAXX expression, and loss of RB expression. The final diagnosis rendered was "high-grade neuroendocrine neoplasm" with discussion of both entities in the differential. Post-operatively, the patient remains alive with stable metastases.

conclusionsThis case highlights the diagnostic complexities of distinguishing G3 PanNET and PanNEC even with the support of ancillary immunohistochemical and molecular studies. In addition, such cases raise the possibility that G3 PanNET and PanNEC may lie on a spectrum of disease with potential biological overlap.

Indexed as

Biomarkers, TumorCarcinoma, NeuroendocrineNeuroendocrine TumorsPancreatic NeoplasmsDiagnosis, DifferentialFemaleHumansImmunohistochemistryMiddle AgedNeoplasm GradingBiomarkers, TumorNeuroendocrine carcinomaNeuroendocrine tumorPancreas

Identifiers

PMID39267076
PMCPMC11391758

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.